Logo image of ELEV

ELEVATION ONCOLOGY INC (ELEV) Stock Fundamental Analysis

NASDAQ:ELEV - Nasdaq - US28623U1016 - Common Stock - Currency: USD

0.6074  -0.04 (-6.53%)

After market: 0.61 +0 (+0.43%)

Fundamental Rating

2

Overall ELEV gets a fundamental rating of 2 out of 10. We evaluated ELEV against 572 industry peers in the Biotechnology industry. The financial health of ELEV is average, but there are quite some concerns on its profitability. ELEV is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ELEV has reported negative net income.
ELEV had a negative operating cash flow in the past year.
ELEV had negative earnings in each of the past 5 years.
In the past 5 years ELEV always reported negative operating cash flow.
ELEV Yearly Net Income VS EBIT VS OCF VS FCFELEV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -20M -40M -60M -80M

1.2 Ratios

With a Return On Assets value of -39.46%, ELEV perfoms like the industry average, outperforming 56.84% of the companies in the same industry.
Looking at the Return On Equity, with a value of -60.48%, ELEV is in the better half of the industry, outperforming 60.04% of the companies in the same industry.
Industry RankSector Rank
ROA -39.46%
ROE -60.48%
ROIC N/A
ROA(3y)-57.89%
ROA(5y)-100.9%
ROE(3y)-100.07%
ROE(5y)-155.16%
ROIC(3y)N/A
ROIC(5y)N/A
ELEV Yearly ROA, ROE, ROICELEV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 -100 -200 -300 -400

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ELEV so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ELEV Yearly Profit, Operating, Gross MarginsELEV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023

More info and screens

4

2. Health

2.1 Basic Checks

Compared to 1 year ago, ELEV has more shares outstanding
Compared to 1 year ago, ELEV has a worse debt to assets ratio.
ELEV Yearly Shares OutstandingELEV Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 10M 20M 30M 40M
ELEV Yearly Total Debt VS Total AssetsELEV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 50M 100M

2.2 Solvency

ELEV has an Altman-Z score of -2.63. This is a bad value and indicates that ELEV is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -2.63, ELEV perfoms like the industry average, outperforming 49.02% of the companies in the same industry.
ELEV has a Debt/Equity ratio of 0.45. This is a healthy value indicating a solid balance between debt and equity.
ELEV has a Debt to Equity ratio of 0.45. This is in the lower half of the industry: ELEV underperforms 74.25% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.45
Debt/FCF N/A
Altman-Z -2.63
ROIC/WACCN/A
WACCN/A
ELEV Yearly LT Debt VS Equity VS FCFELEV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 17.77 indicates that ELEV has no problem at all paying its short term obligations.
ELEV's Current ratio of 17.77 is amongst the best of the industry. ELEV outperforms 92.72% of its industry peers.
ELEV has a Quick Ratio of 17.77. This indicates that ELEV is financially healthy and has no problem in meeting its short term obligations.
ELEV has a Quick ratio of 17.77. This is amongst the best in the industry. ELEV outperforms 92.72% of its industry peers.
Industry RankSector Rank
Current Ratio 17.77
Quick Ratio 17.77
ELEV Yearly Current Assets VS Current LiabilitesELEV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 50M 100M

More info and screens

1

3. Growth

3.1 Past

ELEV shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 62.04%, which is quite impressive.
EPS 1Y (TTM)62.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%12%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ELEV is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.25% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y43.08%
EPS Next 2Y18.12%
EPS Next 3Y10.53%
EPS Next 5Y8.25%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ELEV Yearly Revenue VS EstimatesELEV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
ELEV Yearly EPS VS EstimatesELEV Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ELEV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ELEV is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ELEV Price Earnings VS Forward Price EarningsELEV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ELEV Per share dataELEV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.12%
EPS Next 3Y10.53%

More info and screens

0

5. Dividend

5.1 Amount

ELEV does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ELEVATION ONCOLOGY INC

NASDAQ:ELEV (2/21/2025, 8:15:34 PM)

After market: 0.61 +0 (+0.43%)

0.6074

-0.04 (-6.53%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2024-11-06/bmo
Earnings (Next)03-04 2025-03-04/amc
Inst Owners56.05%
Inst Owner Change-91.93%
Ins Owners0.27%
Ins Owner Change0.56%
Market Cap35.91M
Analysts87.14
Price Target7.14 (1075.5%)
Short Float %16.85%
Short Ratio3.56
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)6.33%
Min EPS beat(2)-8.46%
Max EPS beat(2)21.12%
EPS beat(4)2
Avg EPS beat(4)5.67%
Min EPS beat(4)-11.52%
Max EPS beat(4)21.54%
EPS beat(8)3
Avg EPS beat(8)1.39%
EPS beat(12)4
Avg EPS beat(12)-2.89%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)3.26%
EPS NQ rev (3m)3.26%
EPS NY rev (1m)0.89%
EPS NY rev (3m)-1.29%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.52
P/tB 0.52
EV/EBITDA N/A
EPS(TTM)-0.82
EYN/A
EPS(NY)-0.93
Fwd EYN/A
FCF(TTM)-0.65
FCFYN/A
OCF(TTM)-0.65
OCFYN/A
SpS0
BVpS1.17
TBVpS1.17
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -39.46%
ROE -60.48%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-57.89%
ROA(5y)-100.9%
ROE(3y)-100.07%
ROE(5y)-155.16%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.45
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 17.77
Quick Ratio 17.77
Altman-Z -2.63
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)100%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)62.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%12%
EPS Next Y43.08%
EPS Next 2Y18.12%
EPS Next 3Y10.53%
EPS Next 5Y8.25%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y17.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-103.84%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y49.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y49.91%
OCF growth 3YN/A
OCF growth 5YN/A